8-K: Kyntra Bio Reports Q4/FY25 Results, Advances Key Programs

Kyntra Bio announced its fourth quarter and full year 2025 financial results, highlighting progress in its FG-3246 and roxadustat clinical programs and a cash runway into 2028.

Summary

• Reported total revenue from continuing operations of $1.3 million for the fourth quarter of 2025 and $6.4 million for the full year 2025.
• Net loss from continuing operations was $14.6 million for Q4 2025 and $58.2 million for the full year 2025.
• Ended December 31, 2025, with $109.4 million in cash, cash equivalents, investments, and accounts receivable, projecting a cash runway into 2028.
• The Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and remains on track for interim analysis in the second half of 2026.
• Positive results from an investigator-sponsored Phase 1b/2 study of FG-3246 in combination with enzalutamide in mCRPC were presented at ASCO GU 2026, showing a median radiographic progression-free survival (rPFS) of 7.0 months in the overall cohort, and 10.1 months in patients who progressed on only one prior ARPI.
• Submitted the pivotal Phase 3 clinical trial protocol for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden to the U.S. Food and Drug Administration (FDA).
• Roxadustat was granted Orphan Drug Designation from the FDA for the treatment of MDS.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to strong clinical progress for both key assets, significant improvement in full-year net loss from continuing operations, and a robust cash runway into 2028, despite a decline in current revenue.

Positives

• Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide, further validating key Phase 2 monotherapy design elements for mCRPC.
• The FG-3246 Phase 2 monotherapy trial is actively enrolling and on track for interim analysis in the second half of 2026.
• Roxadustat received Orphan Drug Designation from the FDA for the treatment of MDS, which can provide market exclusivity and development incentives.
• The pivotal Phase 3 clinical trial protocol for roxadustat was submitted to the FDA, with the goal of starting the trial in the second half of 2026.
• A strong cash position of $109.4 million as of December 31, 2025, provides a projected cash runway into 2028.
• Net loss from continuing operations for the full year 2025 significantly improved to $58.2 million, compared to $153.1 million for the full year 2024.
• The company reported a net income of $183.452 million for the full year 2025, a substantial improvement from a net loss of $47.579 million in 2024, primarily driven by income from discontinued operations.

Negatives

• Total revenue from continuing operations for the full year 2025 significantly decreased to $6.4 million, compared to $29.6 million for the full year 2024.
• Total revenue from continuing operations for the fourth quarter of 2025 decreased to $1.3 million, compared to $3.1 million for the fourth quarter of 2024.
• Net loss from continuing operations for the fourth quarter of 2025 increased to $14.6 million ($3.61 net loss per basic and diluted share), compared to a net loss of $8.7 million ($2.15 net loss per basic and diluted share) for the same period in 2024.

Risks

• Actual results may differ materially from forward-looking statements due to risks and uncertainties related to the continued progress and timing of various programs.
• Risks and uncertainties are associated with the enrollment and results from ongoing and potential future clinical trials.
• Uncertainties exist regarding regulatory interactions and approvals.
• Other matters described in Kyntra Bio's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, including the risk factors set forth therein, could impact results.

Future Outlook

Kyntra Bio expects interim results from its FG-3246 Phase 2 monotherapy trial in the second half of 2026. The company also intends to start the Phase 3 trial for roxadustat in the second half of 2026, pending feedback from the FDA. The current cash position is projected to fund operating plans into 2028.

Management Comments

• "The encouraging results from the investigator-sponsored combination trial of FG-3246 with enzalutamide provide us with valuable insights and reinforce key design elements in our Phase 2 monotherapy study."
• "Our Phase 2 monotherapy trial of FG-3246 is progressing as planned, with interim results expected in the second half of 2026."
• "Additionally, we have submitted the Phase 3 trial protocol for roxadustat for the treatment of anemia in patients with LR-MDS and expect feedback from the FDA shortly, with the intention to start a Phase 3 trial in the second half of 2026."
• "With our successful transformation in 2025, we are well-positioned to execute our strategic plan in 2026 and anticipate an exciting year ahead."

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry heavily relies on successful clinical trial progression and regulatory approvals. Kyntra Bio's advancement of FG-3246 and roxadustat, particularly with Orphan Drug Designation for MDS, positions it in competitive oncology and rare disease markets. The focus on antibody-drug conjugates (ADCs) like FG-3246 aligns with a growing trend in targeted cancer therapies, while roxadustat addresses a significant unmet need in lower-risk myelodysplastic syndromes (LR-MDS) anemia.

Comparison to Industry Standards

• The median radiographic progression-free survival (rPFS) of 7.0 months (and 10.1 months in a subset) for FG-3246 in combination with enzalutamide in mCRPC is a promising indicator. For context, standard second-line therapies for mCRPC often show rPFS in the range of 4-8 months, suggesting FG-3246's results are competitive, particularly the 10.1 months observed in patients with only one prior androgen receptor pathway inhibitor (ARPI).
• Orphan Drug Designation for roxadustat in MDS is a significant regulatory milestone, offering market exclusivity and development incentives, which is a standard benefit for drugs addressing rare diseases.
• The cash runway into 2028, supported by $109.4 million in liquid assets, represents a strong financial position for a clinical-stage biopharmaceutical company, providing stability for ongoing development without immediate pressure for dilutive financing, especially when compared to many smaller biotech firms that often have 12-18 months of cash.

Stakeholder Impact

• Shareholders: Potential for increased value through clinical trial success and extended cash runway, but also risk from declining revenue from continuing operations.
• Patients: Potential for new treatment options for metastatic castration-resistant prostate cancer (mCRPC) and lower-risk myelodysplastic syndromes (LR-MDS) anemia if trials are successful.
• Employees: Continued employment stability due to the extended cash runway and ongoing development programs.
• Regulatory Authorities: Ongoing engagement with the FDA through Orphan Drug Designation and Phase 3 protocol submission.

Next Steps

• Interim analysis of the FG-3246 Phase 2 monotherapy trial in the second half of 2026.
• Receive feedback from the FDA on the roxadustat Phase 3 trial protocol.
• Start the Phase 3 trial for roxadustat in the second half of 2026.
• Explore internal development or strategic partnership opportunities for roxadustat.
• Host a conference call and webcast presentation on March 16, 2026, to discuss financial results and provide a business update.

Key Dates

Recommendation

Kyntra Bio shows promising clinical progress with FG-3246 and roxadustat, including positive early data and regulatory milestones like Orphan Drug Designation, backed by a solid cash runway into 2028. This provides a strong foundation for future growth. However, the significant decline in revenue from continuing operations indicates challenges in its current commercial activities or a shift in focus, and the Q4 net loss from continuing operations worsened. While the full-year net loss from continuing operations improved and overall net income was positive due to discontinued operations, the core business's revenue trend warrants caution. Investors should hold to monitor the interim Phase 2 results for FG-3246 and the initiation of the roxadustat Phase 3 trial, as these milestones will be critical determinants of future value.

Keywords

Kyntra Bio, KYNB, financial results, Q4 2025, full year 2025, SEC filing, 8-K, biopharmaceutical, oncology, rare disease, FG-3246, ADC, CD46, mCRPC, metastatic castration-resistant prostate cancer, roxadustat, anemia, LR-MDS, myelodysplastic syndromes, FDA, Orphan Drug Designation, clinical trial, Phase 2, Phase 3, cash runway, financial reporting